However, Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, cautioned that while the notion of a heart hormone cancer treatment has a "seductive" appeal, much more research is required.
"Unfortunately, in general, we see a lot of experiments that seem promising in test tubes and animals but for whatever reason don't translate into anything that has treatment benefit," he said. "And specifically, in this case, we're talking about normal hormones already in circulation in our body, and normal receptors on cancer cells.
"So, in a perhaps simplistic, but nonetheless important, way, the question then arises: Why do people get cancer in the first place if this hormonal mechanism is so effective?" Lichtenfeld said. "And I do not see that the researchers clearly suggest an underlying rational mechanism to explain why this would happen and work in humans.
"So, I understand here that a researcher has lost a wife and a mother to cancer, and I know it's personal," he acknowledged. "And I've certainly learned to never say never. But it would take considerably more replication of this work before I could say this theory will gain traction."
More information
For additional information on current cancer treatment options, visit the American Cancer Society.
SOURCES: Len Lichtenfeld, M.D., FACP, deputy chief medical officer, American Cancer Society, Atlanta; David L. Vesely, M.D., Ph.D., professor, medicine, department of internal medicine, and director, department of molecular pharmacology and physiology, University of South Florida Cardiac Hormone Center, Tampa; April 9, 2008, presentation, Experimental Biology meeting, San Diego
| Copyright©2008 ScoutNews,LLC. All rights reserved |